UNSPSC 51351515: Proligestone

This classification denotes a therapeutic progestin with the molecular formula C24H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55772LJ01V, chemically known as 14,17-dihydroxypregn-4-ene-3,20-dione, cyclic acetal with propionaldehyde but generally known as proligestone, which bears US NIH Compound Identifier 71906. European Medicines Agency schedules Proligestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10081MIG.

UNSPSC 51351515 Proligestone is a Commodity code for a specific veterinary pharmaceutical ingredient used in animal reproductive management. State and local government procurement under this code focuses on purchasing proligestone-containing products for animal health and control programs, particularly in wildlife management, animal shelters, and veterinary services operated by or contracted to public agencies. The code sits within broader pharmaceutical procurement frameworks where state and local entities source medications through cooperative purchasing alliances and authorized wholesaler networks. Issuing bodies include state departments of agriculture, state wildlife agencies, county animal control offices, and municipal animal shelters that maintain veterinary programs.

The recent contract opportunity reflects the broader pharmaceutical procurement environment in which proligestone products are acquired. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. While the RFP scope encompasses a wide range of generic pharmaceuticals and OTC products rather than proligestone specifically, it demonstrates the cooperative purchasing model and authorized wholesaler distribution channels through which state and local entities procure pharmaceutical inventory. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), comply with cGMP and DSCSA requirements, and meet pricing competitiveness criteria weighted at 75 percent of evaluation. Contract awards are effective July 1, 2026, with a two-year initial term for new responders and optional extensions at MMCAP's discretion.